Advances of Cell & Gene Therapy: Neurosurgeons’ Contributions from Taiwan

When:  Dec 10, 2021 from 09:00 to 10:00 (CST)
Thursday, December 9 - 17:00 PDT; 20:00 EDT
What time is this for me?

Advances of Cell & Gene Therapy: Neurosurgeons’ Contributions from Taiwan 

An ISCT Asia Regional Executive Committee Webinar
Part 4 of 4 of the ISCT Asia Regional Webinar Series

Sponsored in part by:

Webinar Description:

This webinar will review and share the most recent advances of cell & gene therapy and emerging technologies in malignant brain tumor treatment, the development of newer generation of chimeric antigen receptor-T cells for cancer treatment, as well as the clinical experiences of using mesenchymal stem cells to treat spinal cord injury patients. Three neurosurgeons from Taiwan will share their clinical and research experiences during their clinical career in the United States and Taiwan.

Chaired By: 

Oscar Lee, MD, PhD
Immediate Past Asia Regional VP, ISCT
Vice Superintendent
China Medical University Hospital
Taiwan

Professor Oscar Lee, MD, PhD is an internationally renowned orthopaedic surgeon-scientist who works on basic science and translational application of mesenchymal stromal cells. He has published more than 140 peer-reviewed stem cell research-related papers with a total citation of more than 10,000 times. He is now Vice Superintendent of China Medical University Hospital and Distinguished Professor of China Medical University in Taichung, Taiwan. Also, Professor Lee is the immediate past Vice President of ISCT, Asia Region.
















Speakers:

John Kuo, MD, PhD
Vice President
China Medical University
Taiwan

Emerging Therapeutic Strategies for Malignant Brain Tumors

Dr. John S. Kuo, MD, PhD is currently the Vice President for Medical Affairs of China Medical University. With his clinical excellence and professional achievements from top US universities and academic medical centers, Dr. Kuo helps advance Taiwan’s biomedical field to the world class level and cultivate a new generation of talents to further contribute to our society.

Dr. Kuo is an internationally renowned neurosurgeon specializing in complex brain tumor surgery, pituitary surgery and stereotactic radiosurgery. He has created and led multidisciplinary clinical programs of excellence. Dr. Kuo led and co-authored influential national guidelines for brain tumor clinical management and is a leader in the Brain Tumor Executive Committee and other major US neurosurgery, neuro-oncology, and medical societies. Along with outstanding clinical performance, Dr. Kuo has received many research grants and academic honors. He was elected to the American Academy of Neurological Surgeons as a top US academic neurosurgeon out of over 5000 US/Canadian neurosurgeons and elected to the Society of University Surgeons as a top US surgeon across all surgical specialties. Over many years, Dr. Kuo was chosen by his peers as one of America’s Top Surgeons and Castle Connolly America’s Top Doctors.

Der-Yang Cho, MD, PhD 
Superintendent
China Medical University Hospital
Taiwan

Development of Chimeric Antigen Receptor-T cells for Cancer Treatment

Professor Der-Yang Cho, MD, PhD is the Superintendent of China Medical University Hospital, in Taichung, Taiwan.

Cheng-Di Chiu, MD, PhD 
Director of Minimal Invasive Spine,
Department of Neurosurgery
Deputy Director of Spine Surgery
China Medical University Hospital
Taiwan

Treatment of Spinal Cord Injury Patients with Mesenchymal Stem Cells: Sharing of Clinical Experiences

Dr. Cheng-Di Chiu is a clinical-scientist and a neurosurgeon of China Medical University and University Hospital. His work mainly focuses on the biological mechanism participated in the formation/progression of hemorrhagic stroke by studying the key cell types and immunological factors which regulate the integrity of blood-brain barrier in early period of injury. He also investigates surgical and interventional approaches used to mitigate symptoms from disc degenerative disease. As a member of CMUH Spine Center, he recently designs and performs MSC-based therapy for sub-acute stage spinal cord injury, which was one of the leading protocol accepted by Taiwanese government and has been launched in CMUH since May 2021.



ISCT_Asia_Dec_2021_Webinar_Graphic_Card_V2.png